AWH:NYE-Aspira Women's Health Inc (USD)

COMMON STOCK | Diagnostics & Research | NYE

Last Closing Price

USD 6.24

Change

0.00 (0.00)%

Market Cap

USD 0.65B

Volume

0.44M

Average Target Price

N/A
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women in the United States. The company provides sells OVA1, Overa, and Ova1PLUS risk of malignancy tests for ovarian cancer. It also offers ASPiRA GenetiX, a genetic test for specific women's health diseases. In addition, the company owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, it is developing diagnostic algorithms, as well as a high-risk screening algorithm for patients who are genetically predisposed to ovarian cancer. Aspira Women's Health Inc. has entered into a collaborative research agreement with Baylor Genetics to co-develop a novel ovarian cancer early-detection test. It serves physicians, physician office laboratories, and hospital laboratories. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was founded in 1993 and is headquartered in Austin, Texas.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-18 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
TMO Thermo Fisher Scientific Inc

N/A

USD199.41B 41.26 25.91
DHR Danaher Corporation

N/A

USD168.18B 47.73 33.50
DHR-PA Danaher Corporation

N/A

USD148.62B 325.78 N/A
PHG Koninklijke Philips N.V

N/A

USD49.74B 34.32 36.22
A Agilent Technologies, Inc

N/A

USD38.73B 54.87 32.77
IQV IQVIA Holdings Inc

N/A

USD36.00B 207.27 24.17
MTD Mettler-Toledo International I..

N/A

USD28.99B 51.22 35.58
LH Laboratory Corporation of Amer..

N/A

USD21.79B 25.95 12.83
DGX Quest Diagnostics Incorporated

N/A

USD16.76B 15.34 10.31
WAT Waters Corporation

N/A

USD16.65B 33.43 23.46

ETFs Containing AWH

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -7.00% 5% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.00% 5% F 4% F
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain -93.95% 6% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -93.95% 6% F 1% F
Average Annual (5 Year Horizon)  
Capital Gain 6.03% 30% F 70% C-
Dividend Return 3.22% 90% A- 71% C-
Total Return 9.25% 30% F 72% C-
Risk Return Profile  
Volatility (Standard Deviation) 31.00% 25% F 21% F
Risk Adjusted Return 29.85% 30% F 49% F
Market Capitalization 0.65B 30% F 46% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 17.10 88% B+ 53% F
Price/Book Ratio 44.64 12% F 1% F
Price / Cash Flow Ratio -50.09 95% A 96% A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -115.34% 6% F 3% F
Return on Invested Capital -163.73% 5% F 1% F
Return on Assets -50.63% 10% F 1% F
Debt to Equity Ratio 12.58% 79% C+ 85% B
Technical Ratios  
Short Ratio 16.66 5% F 1% F
Short Percent 21.13% 6% F 25% F
Beta 3.28 5% F 2% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector